SCHEMBL24328356

SCHEMBL24328356

CS(=O)(=O)N1CCc2cccc(Nc3nc(Cl)ncc3F)c21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 2/20 0.41
AURKA O14965 3/20 0.37
AURKB Q96GD4 2/20 0.37
GSK3A P49840 1/20 0.36
LRRK2 Q5S007 1/20 0.36
MAPK15 Q8TD08 1/20 0.36
CAMKK2 Q96RR4 1/20 0.36
EGFR P00533 1/20 0.36
ITK Q08881 1/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TUBB4A P04350 5/20 0.36
TUBB P07437 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29661413 1.00 GLO1 (0.41) GLO1AURKAAURKBGSK3ALRRK2
SCHEMBL24327468 0.89 CDK9 (0.43) LRRK2EGFRNPC1RAB9AALK
SCHEMBL29661342 0.89 CDK9 (0.43) LRRK2EGFRNPC1RAB9AALK
SCHEMBL24327587 0.88 BRD4 (0.37) NPC1RAB9ATUBB4ATUBBTUBA3C
SCHEMBL29661472 0.88 BRD4 (0.37) NPC1RAB9ATUBB4ATUBBTUBA3C
SCHEMBL24327315 0.88 ZAP70 (0.41) EGFRNPC1RAB9AALDH1A1TUBB4A
SCHEMBL29661317 0.88 ZAP70 (0.41) EGFRNPC1RAB9AALDH1A1TUBB4A
SCHEMBL30942615 0.87 CHEK1 (0.42) AURKALRRK2EGFRMAPTTP53
SCHEMBL24327335 0.85 TUBB4A (0.42) LRRK2NPC1RAB9ATUBB4ATUBB
SCHEMBL29661398 0.85 TUBB4A (0.42) LRRK2NPC1RAB9ATUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117794914-A Pyrimidine-2, 4-diamine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient 韩国化学研究院 2024-03-29 CN disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 GLO1 3308/4885AURKA 45/4885AURKB 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.